Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003).

@article{Turner2004SusceptibilityOM,
  title={Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003).},
  author={Philip J. Turner},
  journal={Diagnostic microbiology and infectious disease},
  year={2004},
  volume={50 4},
  pages={291-3}
}
  • Philip J. Turner
  • Published 2004 in Diagnostic microbiology and infectious disease
A total of 30,634 global Enterobacteriaceae isolates collected from the MYSTIC (Meropenem Yearly Surveillance Test Information Collection) Programme were tested using a reference methodology against meropenem and seven other broad-spectrum agents commonly used in the hospital setting (1997-2003). The most active compound was meropenem (99.6% susceptible), followed by imipenem (98.4%), cefepime (94.0%), gentamicin (86.8%), piperacillin/tazobactam (85.8%), ceftazidime (85.0%), ciprofloxacin (84.6… CONTINUE READING